{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:56:59Z","timestamp":1792789019703,"version":"4.5.0"},"reference-count":172,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T00:00:00Z","timestamp":1591920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Fondo de Investigaci\u00f3n Sanitaria","award":["PI18\/01383"],"award-info":[{"award-number":["PI18\/01383"]}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["Una manera de hacer Europe"],"award-info":[{"award-number":["Una manera de hacer Europe"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004099","name":"Ligue Contre le Cancer","doi-asserted-by":"publisher","award":["CD76"],"award-info":[{"award-number":["CD76"]}],"id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Mantle cell lymphoma (MCL) is a rare but aggressive B-cell hemopathy characterized by the translocation t(11;14)(q13;q32) that leads to the overexpression of the cell cycle regulatory protein cyclin D1. This translocation is the initial event of the lymphomagenesis, but tumor cells can acquire additional alterations allowing the progression of the disease with a more aggressive phenotype and a tight dependency on microenvironment signaling. To date, the chemotherapeutic-based standard care is largely inefficient and despite the recent advent of different targeted therapies including proteasome inhibitors, immunomodulatory drugs, tyrosine kinase inhibitors, relapses are frequent and are generally related to a dismal prognosis. As a result, MCL remains an incurable disease. In this review, we will present the molecular mechanisms of drug resistance learned from both preclinical and clinical experiences in MCL, detailing the main tumor intrinsic processes and signaling pathways associated to therapeutic drug escape. We will also discuss the possibility to counteract the acquisition of drug refractoriness through the design of more efficient strategies, with an emphasis on the most recent combination approaches.<\/jats:p>","DOI":"10.3390\/cancers12061565","type":"journal-article","created":{"date-parts":[[2020,6,15]],"date-time":"2020-06-15T12:16:57Z","timestamp":1592223417000},"page":"1565","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Management of Drug Resistance in Mantle Cell Lymphoma"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0245-2257","authenticated-orcid":false,"given":"Ga\u00ebl","family":"Rou\u00e9","sequence":"first","affiliation":[{"name":"Lymphoma Translational Group, Josep Carreras Leukaemia Research Institute (IJC), 08916 Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7278-9651","authenticated-orcid":false,"given":"Brigitte","family":"Sola","sequence":"additional","affiliation":[{"name":"MICAH Team, INSERM U1245, UNICAEN, CEDEX 5, 14032 Caen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,6,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/bjh.14699","article-title":"Incidence and survival trends in mantle cell lymphoma","volume":"181","author":"Epperla","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.critrevonc.2011.05.001","article-title":"Mantle cell lymphoma","volume":"82","author":"Cortelazzo","year":"2012","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_3","unstructured":"Swerdlow, S.H., World Health Organization, and International Agency for Research on Cancer (2017). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, WHO."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/hon.2596","article-title":"The modern approach to mantle cell lymphoma","volume":"37","author":"Rule","year":"2019","journal-title":"Hematol. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1172\/JCI61272","article-title":"Molecular pathogenesis of mantle cell lymphoma","volume":"122","author":"Jares","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1365-2141.2008.07124.x","article-title":"Advances in the understanding of mantle cell lymphoma","volume":"142","author":"Jares","year":"2008","journal-title":"Br. J. Haematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.3324\/haematol.2009.010264","article-title":"SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype","volume":"94","author":"Mozos","year":"2009","journal-title":"Haematologica"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1182\/blood-2014-04-569566","article-title":"SOX11 promotes tumor angiogenesis through transcriptional regulation of PDGFA in mantle cell lymphoma","volume":"124","author":"Palomero","year":"2014","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/ajh.24094","article-title":"Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management","volume":"90","author":"Vose","year":"2015","journal-title":"Am. J. Hematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.ccell.2016.09.014","article-title":"Decoding the DNA methylome of mantle cell lymphoma in the light of the entire B cell cineage","volume":"30","author":"Beekman","year":"2016","journal-title":"Cancer Cell"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1158\/0008-5472.CAN-09-3419","article-title":"Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma","volume":"70","author":"Salamero","year":"2010","journal-title":"Cancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.2008.19.6121","article-title":"Outcome of deferred initial therapy in mantle-cell lymphoma","volume":"27","author":"Martin","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"djw263","DOI":"10.1093\/jnci\/djw263","article-title":"Recommendations for Clinical Trial Development in Mantle Cell Lymphoma","volume":"109","author":"Spurgeon","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.hoc.2019.03.002","article-title":"Mantle Cell Lymphoma: Current and Emerging Treatment Strategies and Unanswered Questions","volume":"33","author":"Diamond","year":"2019","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Yan, F., Gopal, A.K., and Graf, S.A. (2017). Targeted drugs as maintenance therapy after autologous stem cell transplantation in patients with mantle cell lymphoma. Pharmaceuticals, 10.","DOI":"10.3390\/ph10010028"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1200920","article-title":"Treatment of older patients with mantle-cell lymphoma","volume":"367","author":"Hoster","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S1470-2045(18)30685-5","article-title":"Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: Final overall survival results of a randomised, open-label, phase 3 study","volume":"19","author":"Robak","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s12185-016-2164-2","article-title":"Current treatment strategies in relapsed\/refractory mantle cell lymphoma: Where are we now?","volume":"105","author":"Atilla","year":"2017","journal-title":"Int. J. Hematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1002\/cncr.29498","article-title":"Long-term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning","volume":"121","author":"Vaughn","year":"2015","journal-title":"Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/bjh.15723","article-title":"Allogeneic stem cell transplantation as part of front line therapy for Mantle cell lymphoma","volume":"184","author":"Rule","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","article-title":"Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma","volume":"24","author":"Fisher","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","article-title":"Phase III study to evaluate temsirolimus compared with investigator\u2019s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma","volume":"27","author":"Hess","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1200\/JCO.2013.49.2835","article-title":"Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: Phase II MCL-001 (EMERGE) study","volume":"31","author":"Goy","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"5291","DOI":"10.1158\/1078-0432.CCR-07-0871","article-title":"Bortezomib for the treatment of mantle cell lymphoma","volume":"13","author":"Kane","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/CCO.0b013e32835de8ee","article-title":"Temsirolimus in the treatment of mantle cell lymphoma: Frequency and management of adverse effects","volume":"25","author":"Bouabdallah","year":"2013","journal-title":"Curr. Opin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1177\/2040620714532124","article-title":"Lenalidomide in relapsed or refractory mantle cell lymphoma: Overview and perspective","volume":"5","author":"Desai","year":"2014","journal-title":"Ther. Adv. Hematol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1182\/blood-2015-03-635326","article-title":"Long-term follow-up of MCL patients treated with single-agent ibrutinib: Updated safety and efficacy results","volume":"126","author":"Wang","year":"2015","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1097\/CJI.0b013e3181ac6138","article-title":"Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor","volume":"32","author":"Kochenderfer","year":"2009","journal-title":"J. Immunother."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-Cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4597","DOI":"10.1182\/blood-2011-10-388298","article-title":"Selective CDK4\/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma","volume":"119","author":"Leonard","year":"2012","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/bjh.12769","article-title":"Ofatumumab monotherapy in relapsed\/refractory mantle cell lymphoma\u2014A phase II trial","volume":"165","author":"Furtado","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1200\/JCO.2012.46.9585","article-title":"Obinutuzumab (GA101) monotherapy in relapsed\/refractory diffuse large B-cell lymphoma or mantle-cell lymphoma: Results from the phase II GAUGUIN study","volume":"31","author":"Morschhauser","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1182\/blood-2013-11-537555","article-title":"A phase 1 study of the PI3K\u03b4 inhibitor idelalisib in patients with relapsed\/refractory mantle cell lymphoma (MCL)","volume":"123","author":"Kahl","year":"2014","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1600-0609.2005.00546.x","article-title":"Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma","volume":"76","author":"Heider","year":"2006","journal-title":"Eur. J. Haematol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1158\/1078-0432.CCR-15-0624","article-title":"A phase I\/II multicenter, open-label study of the oral histone deacetylase inhibitor abexinostat in relapsed\/refractory lymphoma","volume":"22","author":"Evens","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.3324\/haematol.2011.053173","article-title":"A multicenter phase II trial (SAKK 36\/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma","volume":"97","author":"Renner","year":"2012","journal-title":"Haematologica"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1200\/JCO.2015.63.5904","article-title":"Mantle cell lymphoma","volume":"34","author":"Cheah","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1182\/blood-2013-07-517177","article-title":"The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells","volume":"123","author":"Zhang","year":"2014","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"18250","DOI":"10.1073\/pnas.1314608110","article-title":"Landscape of somatic mutations and clonal evolution in mantle cell lymphoma","volume":"110","author":"Bea","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1101\/gad.1256504","article-title":"Living with or without cyclins and cyclin-dependent kinases","volume":"18","author":"Sherr","year":"2004","journal-title":"Genes Dev."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S1535-6108(03)00028-X","article-title":"The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma","volume":"3","author":"Rosenwald","year":"2003","journal-title":"Cancer Cell"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"73558","DOI":"10.18632\/oncotarget.12434","article-title":"CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma","volume":"7","author":"Mohanty","year":"2016","journal-title":"Oncotarget"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.3109\/10428194.2011.593272","article-title":"siRNAs targeting cyclin D1 and cyclin D2 enhance the cytotoxicity of chemotherapeutic agents in mantle cell lymphoma cell lines","volume":"52","author":"Tiemann","year":"2013","journal-title":"Leuk. Lymphoma"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41417-018-0022-5","article-title":"Genomic landscape and prognostic analysis of mantle cell lymphoma","volume":"25","author":"Yang","year":"2018","journal-title":"Cancer Gene Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1073\/pnas.0510441103","article-title":"Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma","volume":"103","author":"Greiner","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood-2017-04-779736","article-title":"TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy","volume":"130","author":"Eskelund","year":"2017","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1182\/blood-2017-07-797019","article-title":"Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network","volume":"131","author":"Aukema","year":"2018","journal-title":"Blood"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1182\/blood-2011-11-391474","article-title":"Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma","volume":"119","author":"Kridel","year":"2012","journal-title":"Blood"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1182\/blood-2013-01-478834","article-title":"The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma","volume":"121","author":"Meissner","year":"2013","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nm.3435","article-title":"Pharmacological and genomic profiling identifies NF-kappaB-targeted treatment strategies for mantle cell lymphoma","volume":"20","author":"Rahal","year":"2013","journal-title":"Nat. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"38180","DOI":"10.18632\/oncotarget.9500","article-title":"Genetic heterogeneity in primary and relapsed mantle cell lymphomas: Impact of recurrent CARD11 mutations","volume":"7","author":"Wu","year":"2016","journal-title":"Oncotarget"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/leu.2014.263","article-title":"Functional characterization of BTKC481S mutation that confers ibrutinib resistance: Exploration of alternative kinase inhibitors","volume":"29","author":"Cheng","year":"2015","journal-title":"Leukemia"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1158\/2159-8290.CD-14-0098","article-title":"Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma","volume":"4","author":"Chiron","year":"2014","journal-title":"Cancer Discov."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.critrevonc.2016.08.008","article-title":"ATM mutation and radiosensitivity: An opportunity in the therapy of mantle cell lymphoma","volume":"107","author":"Ahmed","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1182\/blood-2008-07-170183","article-title":"Uniparental disomies, homozygous deletions, amplifications, and target genes in mantle cell lymphoma revealed by integrative high-resolution whole-genome profiling","volume":"113","author":"Salaverria","year":"2009","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/gcc.20277","article-title":"Differential effect of epigenetic alterations and genomic deletions of CDK inhibitors [p16(INK4a),p15(INK4b),p14(ARF)] in mantle cell lymphoma","volume":"45","author":"Hutter","year":"2005","journal-title":"Genes. Chromosomes Cancer"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.exphem.2009.04.012","article-title":"Identified hidden genomic changes in mantle cell lymphoma using high-resolution single nucleotide polymorphism genomic array","volume":"37","author":"Kawamata","year":"2009","journal-title":"Exp. Hematol."},{"key":"ref_62","first-page":"2409","article-title":"BMI-1 gene amplification and overexpression in hematological malignancies occur mainly in mantle cell lymphomas","volume":"61","author":"Tort","year":"2001","journal-title":"Cancer Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1365-2141.2009.07791.x","article-title":"Detection of gene copy number aberrations in mantle cell lymphoma by a single quantitative multiplex PCR assay: Clinicopathological relevance and prognosis value","volume":"146","author":"Jardin","year":"2009","journal-title":"Br. J. Haematol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/nrc.2017.121","article-title":"Targeting B cell receptor signalling in cancer: Preclinical and clinical advances","volume":"18","author":"Burger","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"5365","DOI":"10.1158\/1078-0432.CCR-14-0010","article-title":"Ibrutinib for the treatment of mantle cell lymphoma","volume":"20","author":"Herrera","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"3088","DOI":"10.1182\/blood-2011-03-343434","article-title":"Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases","volume":"118","author":"Hadzidimitriou","year":"2011","journal-title":"Blood"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1182\/blood-2013-02-482125","article-title":"Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients","volume":"122","author":"Chang","year":"2013","journal-title":"Blood"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s13402-011-0019-7","article-title":"Phospho-proteomic analysis of mantle cell lymphoma cells suggests a pro-survival role of B-cell receptor signaling","volume":"34","author":"Pighi","year":"2011","journal-title":"Cell. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1074\/mcp.M800515-MCP200","article-title":"Protein profiling of plasma membranes defines aberrant signaling pathways in mantle cell lymphoma","volume":"8","author":"Boyd","year":"2009","journal-title":"Mol. Cell. Proteom."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1182\/blood-2016-05-718494","article-title":"Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling","volume":"129","author":"Myklebust","year":"2017","journal-title":"Blood"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies","volume":"31","author":"Advani","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1182\/blood-2015-11-681460","article-title":"Pathogenic role of B-cell receptor signaling and canonical NF-kB activation in mantle cell lymphoma","volume":"128","author":"Saba","year":"2016","journal-title":"Blood"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13045-018-0621-5","article-title":"NF-\u03baB signaling and its relevance to the treatment of mantle cell lymphoma","volume":"11","author":"Balaji","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Mastorci, K., Muraro, E., and Pasini, E. (2016). Toll-Like receptor 1\/2 and 5 ligands enhance the expression of cyclin D1 and D3 and induce proliferation in mantle cell lymphoma. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0153823"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/cncr.27792","article-title":"Toll-like receptor-4 signaling in mantle cell lymphoma: Effects on tumor growth and immune evasion","volume":"119","author":"Wang","year":"2013","journal-title":"Cancer"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/hon.2251","article-title":"Concomitant high expression of Toll-like receptor (TLR) and B-cell receptor (BCR) signalling molecules has clinical implications in mantle cell lymphoma","volume":"35","author":"Akhter","year":"2015","journal-title":"Hematol. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1182\/blood-2006-04-015586","article-title":"Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma","volume":"108","author":"Rudelius","year":"2006","journal-title":"Blood"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1159\/000353164","article-title":"Class IA phosphatidylinositol 3-kinase inhibition inhibits cell growth and proliferation in mantle cell lymphoma","volume":"131","author":"Tabe","year":"2013","journal-title":"Acta Haematol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.4049\/jimmunol.1801327","article-title":"ROR1\/CD19 receptor complex promotes growth of mantle cell lymphoma cells independently of the B cell receptor-BTK signaling pathway","volume":"203","author":"Zhang","year":"2019","journal-title":"J. Immunol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3324\/haematol.2014.119115","article-title":"The role of targeted treatment in mantle cell lymphoma: Is transplant dead or alive?","volume":"101","author":"Dreyling","year":"2016","journal-title":"Haematologica"},{"key":"ref_81","first-page":"1","article-title":"Role of Bruton\u2019s tyrosine kinase in B cells and malignancies","volume":"17","author":"Singh","year":"2018","journal-title":"Mol. Cancer"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy","volume":"107","author":"Honigberg","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/bjh.12974","article-title":"Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells","volume":"166","author":"Ma","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1182\/blood-2015-10-673145","article-title":"Postibrutinib outcomes in patients with mantle cell lymphoma","volume":"127","author":"Martin","year":"2016","journal-title":"Blood"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1038\/s41375-019-0575-9","article-title":"Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma","volume":"373","author":"Wang","year":"2019","journal-title":"Leukemia"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1182\/blood.2019852368","article-title":"Acalabrutinib for mantle cell lymphoma","volume":"133","author":"Witzig","year":"2019","journal-title":"Blood"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.3324\/haematol.2011.040659","article-title":"Mesenchymal stromal cells protect mantle cell lymphoma cells from spontaneous and drug-induced apoptosis through secretion of B-cell activating factor and activation of the canonical and non-canonical nuclear factor ~B pathways","volume":"97","author":"Medina","year":"2012","journal-title":"Haematologica"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms14920","article-title":"Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma","volume":"8","author":"Zhao","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.4161\/cc.24928","article-title":"Induction of prolonged early G 1arrest by CDK4\/CDK6 inhibition reprograms lymphoma cells for durable PI3K\u03b4 inhibition through PIK3IP1","volume":"12","author":"Chiron","year":"2013","journal-title":"Cell Cycle"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton\u2019s tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/bjh.15567","article-title":"Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib","volume":"183","author":"Jain","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"5142","DOI":"10.1182\/blood-2007-07-103481","article-title":"Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma","volume":"111","author":"Col","year":"2008","journal-title":"Blood"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"5724","DOI":"10.1158\/1078-0432.CCR-08-3215","article-title":"Phosphatidylinositol 3\u2032-kinase catalytic subunit \u03b1 gene amplification contributes to the pathogenesis of mantle cell lymphoma","volume":"15","author":"Psyrri","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1182\/blood-2012-10-460832","article-title":"P110\u03b1-mediated constitutive PI3K signaling limits the efficacy of p110\u03b4-selective inhibition in mantle cell lymphoma, particularly with multiple relapse","volume":"121","author":"Iyengar","year":"2013","journal-title":"Blood"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nature21406","article-title":"Phosphatidylinositol 3-kinase $\u03b4$ blockade increases genomic instability in B cells","volume":"542","author":"Compagno","year":"2017","journal-title":"Nature"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"eaau1167","DOI":"10.1126\/scitranslmed.aau1167","article-title":"Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma","volume":"11","author":"Zhang","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1158\/1535-7163.MCT-17-0784","article-title":"p110a Inhibition Overcomes Stromal Cell{\\textendash} Mediated Ibrutinib Resistance in Mantle Cell Lymphoma","volume":"17","author":"Guan","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/bjh.16118","article-title":"Single and combined BTK and PI3K$\u03b4$ inhibition with acalabrutinib and ACP-319 in pre-clinical models of aggressive lymphomas","volume":"187","author":"Spriano","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1182\/blood-2010-02-269514","article-title":"Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation","volume":"117","author":"Weniger","year":"2011","journal-title":"Blood"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/978-3-030-38266-7_6","article-title":"Resistance to the proteasome inhibitors: Lessons from multiple myeloma and mantle cell lymphoma","volume":"1233","author":"Quinet","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1182\/blood-2006-07-034173","article-title":"The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak","volume":"109","author":"Villamor","year":"2007","journal-title":"Blood"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1476-4598-7-40","article-title":"Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma","volume":"7","author":"Yang","year":"2008","journal-title":"Mol. Cancer"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Manni, S., Brancalion, A., Mandato, E., Tubi, L.Q., Colpo, A., Pizzi, M., Cappellesso, R., Zaffino, F., Maggio, S.A.D., and Cabrelle, A. (2013). Protein kinase CK2 inhibition down modulates the NF-\u03baB and STAT3 survival pathways, enhances the cellular proteotoxic stress and synergistically boosts the cytotoxic effect of bortezomib on multiple myeloma and mantle cell lymphoma cells. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0075280"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1182\/blood-2005-05-2091","article-title":"The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status","volume":"107","author":"Villamor","year":"2006","journal-title":"Blood"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1158\/1078-0432.CCR-10-3367","article-title":"Treatment-induced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphoma","volume":"17","author":"Weniger","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"5171","DOI":"10.1182\/blood-2008-02-139212","article-title":"Constitutive activation of the Wnt canonical pathway in mantle cell lymphoma","volume":"112","author":"Gelebart","year":"2008","journal-title":"Blood"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/cdd.2013.123","article-title":"The EMT activator ZEB1 promotes tumor growth and determines differential response to chemotherapy in mantle cell lymphoma","volume":"21","author":"Fanlo","year":"2014","journal-title":"Cell Death Differ."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1073\/pnas.0807611106","article-title":"ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells","volume":"16","author":"Wang","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1182\/blood-2010-04-278853","article-title":"The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP\/Grp78","volume":"117","author":"Mozos","year":"2011","journal-title":"Blood"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13045-018-0657-6","article-title":"Cyclin D1-CDK4 activity drives sensitivity to bortezomib in mantle cell lymphoma by blocking autophagy-mediated proteolysis of NOXA","volume":"11","author":"Heine","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1038\/leu.2014.106","article-title":"Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma","volume":"28","author":"Moros","year":"2014","journal-title":"Leukemia"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1182\/blood-2012-06-438937","article-title":"SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma","volume":"121","author":"Vegliante","year":"2013","journal-title":"Blood"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1158\/1541-7786.MCR-10-0131","article-title":"PRDM1 is required for mantle cell lymphoma response to bortezomib","volume":"8","author":"Desai","year":"2010","journal-title":"Mol. Cancer Res."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/bjh.12449","article-title":"Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation","volume":"162","author":"Vose","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1093\/annonc\/mdt366","article-title":"Long-term follow-up of lenalidomide in relapsed\/refractory mantle cell lymphoma: Subset analysis of the NHL-003 study","volume":"24","author":"Zinzani","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1200\/JCO.2014.59.5363","article-title":"Mechanisms of action of lenalidomide in B-cell non-hodgkin lymphoma","volume":"33","author":"Gribben","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/bjh.14866","article-title":"Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell-mediated cytotoxicity","volume":"179","author":"Hagner","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_118","first-page":"2326","article-title":"Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide","volume":"26","author":"Mendy","year":"2019","journal-title":"Leukemia"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ebiom.2017.04.037","article-title":"Synergistic cytotoxicity of lenalidomide and dexamethasone in mantle cell lymphoma via cereblon-dependent targeting of the IL-6\/STAT3\/PI3K axis","volume":"20","author":"Ma","year":"2017","journal-title":"EBioMedicine"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1158\/1078-0432.CCR-13-1569","article-title":"Antitumoral activity of lenalidomide in in vitro and in vivo models of mantle cell lymphomainvolves the destabilization of cyclin D1\/p27KIP1 Complexes","volume":"20","author":"Moros","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Sordo-Bahamonde, C., Vitale, M., Lorenzo-Herrero, S., L\u00f3pez-Soto, A., and Gonzalez, S. (2020). Mechanisms of resistance to NK cell immunotherapy. Cancers, 12.","DOI":"10.3390\/cancers12040893"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"5278","DOI":"10.1158\/1078-0432.CCR-12-0351","article-title":"Counteracting autophagy overcomes resistance to everolimus in mantle cell lymphoma","volume":"18","author":"Rosich","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"115","DOI":"10.4161\/auto.22483","article-title":"Autophagy controls everolimus (RAD001) activity in mantle cell lymphoma","volume":"9","author":"Rosich","year":"2013","journal-title":"Autophagy"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1182\/blood-2006-06-026500","article-title":"Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas","volume":"109","author":"Richter","year":"2007","journal-title":"Blood"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1038\/sj.onc.1208300","article-title":"Genome-wide array-based CGH for mantle cell lymphoma: Identification of homozygous deletions of the proapoptotic gene BIM","volume":"24","author":"Tagawa","year":"2005","journal-title":"Oncogene"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"4455","DOI":"10.1158\/1078-0432.CCR-18-3275","article-title":"Cotargeting of BCL2 with venetoclax and MCL1 with S63845 is synthetically lethal in vivo in relapsed mantle cell lymphoma","volume":"25","author":"Prukova","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Tahir, S.K., Smith, M.L., Hessler, P., Rapp, L.R., Idler, K.B., Park, C.H., Leverson, J.D., and Lam, L.T. (2017). Potential mechanisms of resistance to venetoclax and strategies to circumvent it. BMC Cancer, 17.","DOI":"10.1186\/s12885-017-3383-5"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"6223","DOI":"10.1038\/onc.2016.155","article-title":"FBXO10 deficiency and BTK activation upregulate BCL2 expression in mantle cell lymphoma","volume":"35","author":"Li","year":"2016","journal-title":"Oncogene"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.ccell.2019.04.005","article-title":"BCL2 amplicon loss and transcriptional remodeling drives ABT-199 resistance in B cell lymphoma models","volume":"35","author":"Zhao","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41591-018-0243-z","article-title":"Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma","volume":"25","author":"Agarwal","year":"2018","journal-title":"Nat. Med."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1080\/14737140.2017.1328280","article-title":"Novel agents in mantle cell lymphoma","volume":"17","author":"Tucker","year":"2017","journal-title":"Expert Rev. Anticancer. Ther."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1056\/NEJMoa1505237","article-title":"Lenalidomide plus rituximab as initial treatment for mantle-cell Lymphoma","volume":"373","author":"Ruan","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1182\/blood-2013-08-523845","article-title":"Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: An Eastern Cooperative Oncology Group study (E1405)","volume":"123","author":"Chang","year":"2014","journal-title":"Blood"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/S1470-2045(14)70311-0","article-title":"Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: A non-randomised, phase 1b study","volume":"15","author":"Younes","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1182\/blood-2014-08-597914","article-title":"A phase 1\/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed\/refractory non-Hodgkin lymphoma","volume":"125","author":"Maddocks","year":"2015","journal-title":"Blood"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(15)00438-6","article-title":"Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: A single-centre, open-label, phase 2 trial","volume":"17","author":"Wang","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1715519","article-title":"Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma","volume":"378","author":"Tam","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.immuni.2007.07.009","article-title":"Germinal-Center Organization and Cellular Dynamics","volume":"27","author":"Allen","year":"2007","journal-title":"Immunity"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"4604","DOI":"10.1182\/blood-2008-10-185827","article-title":"Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): Importance for interactions with the stromal microenvironment and specific targeting","volume":"113","author":"Kurtova","year":"2009","journal-title":"Blood"},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"P\u00e9rez-Gal\u00e1n, P., and Rou\u00e9, G. (2015). The challenge of the microenvironment in mantle cell lymphoma. Hodgkin and Non-Hodgkin Lymphomas Seen Through Their Microenvironment: Impact on Diagnosis, Prognosis and Innovative Therapy (Volume 2), Future Medicine Ltd.","DOI":"10.2217\/fmeb2014.14.9"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1159\/000257990","article-title":"Activity of thalidomide and lenalidomide in mantle cell lymphoma","volume":"123","author":"Richardson","year":"2009","journal-title":"Acta Haematol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1038\/sj.leu.2403058","article-title":"Thalidomide therapy induces response in relapsed mantle cell lymphoma","volume":"17","author":"Damaj","year":"2003","journal-title":"Leukemia"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S1470-2045(12)70200-0","article-title":"Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: A phase 1\/2 clinical trial","volume":"13","author":"Wang","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1182\/blood-2018-07-859769","article-title":"Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma","volume":"132","author":"Ruan","year":"2018","journal-title":"Blood"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"958","DOI":"10.3109\/10428194.2014.938333","article-title":"Therapy with bortezomib plus lenalidomide for relapsed\/refractory mantle cell lymphoma: Final results of a phase II trial (CALGB 50501)","volume":"56","author":"Morrison","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1182\/blood-2016-03-704023","article-title":"Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma","volume":"128","author":"Kolstad","year":"2016","journal-title":"Blood"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1158\/1078-0432.CCR-15-0056","article-title":"Ofatumumab Exhibits Enhanced in Vitro and in Vivo Activity Compared to Rituximab in Preclinical Models of Mantle Cell Lymphoma","volume":"21","author":"Barth","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1182\/blood-2010-09-305847","article-title":"Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I\/II distinction of CD20 antibodies","volume":"118","author":"Niederfellner","year":"2011","journal-title":"Blood"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1182\/blood-2016-06-720490","article-title":"Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma","volume":"128","author":"Chiron","year":"2016","journal-title":"Blood"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/01.HS9.0000558632.47592.16","article-title":"Obitunuzumab plus DHAP followed by autologous stem cell transplantation plus obitunuzumab maintenance provides a high MRD response rate in untreated MCL patients. Results of LYMA-101 trial\u2014A LYSA study","volume":"3","author":"Legouill","year":"2019","journal-title":"HemaSphere"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"4158","DOI":"10.1182\/blood-2018-99-113777","article-title":"Ibrutinib plus obinutuzumab and venetoclax in relapsed\/refractory mantle cells lymphoma patients. Results of the OASIS phase I clinical trial","volume":"132","author":"Morschhauser","year":"2018","journal-title":"Blood"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/ejh.13382","article-title":"Obinutuzumab and venetoclax induced complete remission in a patient with ibrutinib-resistant non-nodal leukemic mantle cell lymphoma","volume":"104","author":"Zhou","year":"2020","journal-title":"Eur. J. Haematol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"3980","DOI":"10.1182\/blood.V126.23.3980.3980","article-title":"Ublituximab (TG-1101), a novel glycoengineered anti-CD20 monoclonal antibody, in combination with ibrutinib is highly active in patients with relapsed and\/or refractory mantle cell lymphoma; Results of a phase II trial","volume":"126","author":"Kolibaba","year":"2015","journal-title":"Blood"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1182\/blood.2019002118","article-title":"Ublituximab and umbralisib in relapsed\/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia","volume":"134","author":"Lunning","year":"2019","journal-title":"Blood"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"5556s","DOI":"10.1158\/1078-0432.CCR-07-1167","article-title":"CD74: A new candidate target for the immunotherapy of B-cell neoplasms","volume":"13","author":"Stein","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"4530","DOI":"10.1182\/blood-2010-08-303354","article-title":"Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma","volume":"117","author":"Alinari","year":"2011","journal-title":"Blood"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1200\/JCO.2014.59.1586","article-title":"Bispecific T-cell engager (BiTE) antibody construct Blinatumomab for the treatment of patients with relapsed\/refractory non-Hodgkin lymphoma: Final results from a phase I study","volume":"34","author":"Goebeler","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1182\/blood-2019-124254","article-title":"Blinatumomab\/lenalidomide in relapsed\/refractory non-Hodgkin\u2019s lymphoma: A phase I California Cancer Consortium study of safety, efficacy and immune correlative analysis","volume":"134","author":"Poh","year":"2019","journal-title":"Blood"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"986","DOI":"10.3389\/fgene.2019.00986","article-title":"Recent advances in the targeting of epigenetic regulators in b-cell non-hodgkin lymphoma","volume":"10","author":"Ribeiro","year":"2019","journal-title":"Front. Genet."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1080\/10428194.2018.1520986","article-title":"A novel approach to eliminate therapy-resistant mantle cell lymphoma: Synergistic effects of Vorinostat with Palbociclib","volume":"60","author":"Chaturvedi","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.clml.2018.05.023","article-title":"A Phase II Trial of bortezomib and vorinostat in mantle Cell lymphoma and diffuse large B-cell lymphoma","volume":"18","author":"Yazbeck","year":"2018","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1182\/blood-2015-04-639542","article-title":"Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib","volume":"126","author":"Sun","year":"2015","journal-title":"Blood"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1111\/bjh.16008","article-title":"Phase 1\u20132 study of vorinostat (SAHA), cladribine and rituximab (SCR) in relapsed B-cell non-Hodgkin lymphoma and previously untreated mantle cell lymphoma","volume":"186","author":"Spurgeon","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.clml.2017.09.001","article-title":"Phase 2 open-label study of bortezomib, cladribine, and rituximab in advanced, newly diagnosed, and relapsed\/refractory mantle-cell and indolent lymphomas","volume":"18","author":"Puvvada","year":"2018","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1080\/10428194.2019.1569231","article-title":"Modulation of immune checkpoint molecule expression in mantle cell lymphoma","volume":"60","author":"Harrington","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1","DOI":"10.21037\/aol.2019.05.01","article-title":"Immunologic treatment strategies in mantle cell lymphoma: Checkpoint inhibitors, chimeric antigen receptor (CAR) T-cells, and bispecific T-cell engager (BiTE) molecules","volume":"3","author":"Pritchett","year":"2019","journal-title":"Ann. Lymphoma"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"1982423","DOI":"10.1155\/2018\/1982423","article-title":"Immune checkpoint inhibitors to treat malignant lymphomas","volume":"2018","author":"Witkowska","year":"2018","journal-title":"J. Immunol. Res."},{"key":"ref_168","first-page":"112","article-title":"ALX148 is a high affinity Sirp\u03b1 fusion protein that blocks CD47, enhances the activity of anti-cancer antibodies and checkpoint inhibitors, and has a favorable safety profile in preclinical models","volume":"130","author":"Kauder","year":"2017","journal-title":"Blood"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1182\/blood-2019-123219","article-title":"A Phase 1 sstudy of ALX148, a CD47 blocker, in combination with rituximab in patients with non-Hodgkin lymphoma","volume":"134","author":"Kim","year":"2019","journal-title":"Blood"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"4110","DOI":"10.4049\/jimmunol.1700606","article-title":"CD27-mediated regulatory T cell depletion and effector T cell costimulation both contribute to antitumor efficacy","volume":"199","author":"Wasiuk","year":"2017","journal-title":"J. Immunol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1182\/blood-2019-130449","article-title":"The DIAL study (Dual Immunomodulation in Aggressive Lymphoma): A randomized phase 2 study of CDX-1127 (varlilumab) in combination with nivolumab in patients with relapsed or refractory aggressive B-cell lymphomas (NCI 10089\/NCT03038672)","volume":"134","author":"Villasboas","year":"2019","journal-title":"Blood"},{"key":"ref_172","doi-asserted-by":"crossref","unstructured":"Gopal, A.K., Levy, R., Houot, R., Patel, S.P., Popplewell, L., Jacobson, C., Mu, X.J., Deng, S., Ching, K.A., and Chen, Y. (2020). First-in-human study of utomilumab, a 4-1BB\/CD137 agonist, in combination with rituximab in patients with follicular and other CD20+ non-Hodgkin ymphomas. Clin. Cancer Res., in press.","DOI":"10.1158\/1078-0432.CCR-19-2973"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/6\/1565\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:38:32Z","timestamp":1760175512000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/6\/1565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,12]]},"references-count":172,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,6]]}},"alternative-id":["cancers12061565"],"URL":"https:\/\/doi.org\/10.3390\/cancers12061565","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,12]]}}}